GlassScriptPhysician profile
Charles Peter Catania
NPI 1609037027
$8,109.45
in general payments reported to CMS, 2019-2025
66 companies · $1,733 in 2025
The $1,733 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $981 · 2020: $560 · 2021: $779 · 2022: $1,109 · 2023: $1,434 · 2024: $1,514 · 2025: $1,733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,672 · Education: $8.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,671.59 |
| Education | $8.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,106.78 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $776.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $774.79 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $663.16 | 2019-2025 | Farxiga, Breztri, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $451.87 | 2019-2025 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $400.70 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $328.67 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $233.87 | 2019-2025 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $204.95 | 2019-2025 | |
| Allergan, INC. | $175.22 | 2019-2020 | |
| Abbott Laboratories | $166.43 | 2023-2025 | Freestyle Libre 3, Octrode, Freestyle Libre 2 |
| Teva Pharmaceuticals USA, INC. | $156.54 | 2021-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Corium, LLC | $145.62 | 2022-2024 | Azstarys |
| Merck Sharp & Dohme LLC | $138.34 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Otsuka America Pharmaceutical, INC. | $135.84 | 2019-2025 | Rexulti |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Catania listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.